Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Trial Profile

A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RRx 001 (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Carcinoma; Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REPLATINUM
  • Sponsors EpicentRx
  • Most Recent Events

    • 13 Nov 2019 According to an EpicentRx media release, funding from the recent financing round, enables the company to advance clinical development of our lead cancer programs, including this phase III trial.
    • 05 Nov 2019 According to a EpicentRx media release, first patient has been dosed in this study.
    • 14 Aug 2019 Planned number of patients changed from 120 to 126.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top